Chronic Kidney Diseases
Conditions
Brief summary
The indication of Pu Yang Wan Wu Tang is stroke sequelae, such as half body paralysis, aphasia and muscle weakness. Pu Yang Wan Wu Tang is proved to have the effect of protecting nerve and blood vessel, anti-inflammation, anti-coagulation, dilating peripheral vessel, promot-ing micro circulation, improving hemodynamics, and activating central nerve system. Huangqi could attenuate podocyte injury by regulating the expression and distribu-tion of nephrin and podocin. Huangqi and Danggui are associated with fewer infiltra-tion of macrophages and limitation of renal intrinsic cell activation, which may lead to earlier and persistent reduction of proteinuria. This research will use the compound Chinese medicine, Pu Yang Wan Wu Tang. Those treatments combined Western medicine to assess the efficacy and drug safety on the CKD cases. Series of blood and urine were collected regularly during study to prove the role of Chinese medicine in the treatment of CKD, and to assess their drug safety. The final goal of the plan is to establish the new indication of Pu Yang Wan Wu Tang and enhance the interaction and cooperation between Chinese and Western medicine.
Interventions
DRUGPu Yang Wan Wu Tang plus Pentoxifylline
Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
DRUGPentoxifylline
Pentoxifylline 100mg TID
Sponsors
Taipei Medical University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Participants' age is between 20 to 80 years. * Participants CKD stage are from 2 to 4(eGFR from 89 to 15) * Participants under regular western medicine therapy. * Participants who agree to follow the trial protocol. * Participants who can complete the study treatment and assessments.
Exclusion criteria
* Participants who are already under hemodialysis, Peritoneal Dialysis or kidney transplant. * Participants who are participating in other clinical trials. * Participants with hematopoietic system diseases, severe psychiatric or psychological disorder, or cancer. * Women who are pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Value of eGFR | At baseline |
Secondary
| Measure | Time frame |
|---|---|
| Value of Creatinine | At baseline |
| Value of BUN | At baseline |
| Ratio of Urine Protein/Urine Creatinine | At baseline |
| Value of GOT | At baseline |
| Value of GPT | At baseline |
Countries
Taiwan
Outcome results
None listed